Canaccord cuts Artivion stock price target on revenue outlook
Canaccord has reduced its price target on Artivion Inc. (NYSE: AORT) stock from $40 to $30, maintaining a Buy rating after reviewing the company’s third-quarter results and updated guidance. The medical device company reported a revenue of $123.8 million for Q3 2026, exceeding expectations by 9% year-over-year, while adjusted EBITDA of $22.5 million also surpassed estimates.
Despite this positive performance, Artivion’s stock is currently priced at $25.33, which the analysis suggests is overvalued compared to its Fair Value. The company is expected to see strong momentum with a 16.4% revenue growth over the past year and gross profit margins of 64%. However, Artivion’s revenue growth slowed as PERCLOT revenue starts to roll off in 2027, and the firm adjusted its overall estimates to reflect this change.
The new guidance for fiscal 2026 revenue is now between $484 million and $492 million, with adjusted EBITDA guidance set between $93 million and $98 million. This revision aligns with broader analyst sentiment, as multiple analysts have recently lowered their earnings forecasts for the upcoming period.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
